[1]A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. November 5, 2020.
了解更多ashpublications.org[2]Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL. Hematology News. December 14, 2020.
了解更多 mdedge.com[3]Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.Sci Transl Med. Mar 24,2021.
了解更多 pubmed.ncbi.nlm.nih.gov[4]A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation. ASH Meeting. December 13, 2021.
了解更多 ash.confex.com[5]A novel CD19/CD20 dual synthetic T-cell receptor and antigen receptor (STAR) T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL). EHA Library.. 06/09/2021; 324526; S118.
了解更多 library.ehaweb.org[6] A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. American Journal of Hematology.01 May 2022
了解更多 onlinelibrary.wiley.com